mCureX Therapeutics, Inc. has recently signed a contract for joint research with ToolGen, Inc. to advance the development of gene therapy for rare eye diseases, leveraging mCureX's mRNA technology. The two companies plan to conduct gene corrections in ocular tissues using mCureX's mRNA technology and ToolGen's CRISPR/Cas9 gene-editing technology for the treatment of rare hereditary eye diseases.
End-of-day quote
Other stock markets
|
5-day change | 1st Jan Change | ||
67,100 KRW | -0.59% | +9.82% | -4.42% |
2023 | ToolGen Incorporated announced that it has received KRW 33 billion in funding | CI |
2023 | ToolGen Incorporated announced that it expects to receive KRW 33 billion in funding | CI |
1st Jan change | Capi. | |
---|---|---|
-4.42% | 386M | |
+1.51% | 42.75B | |
+49.22% | 41.61B | |
+8.57% | 41.34B | |
-12.36% | 26.59B | |
+8.92% | 25.49B | |
-25.13% | 18.12B | |
+29.17% | 12.24B | |
-3.12% | 11.76B | |
+6.35% | 11B |
- Stock Market
- Equities
- A199800 Stock
- News ToolGen Incorporated
- MCureX Therapeutics, Inc. Signs Contract for Joint Research with Toolgen, Inc